Ruthenium anticancer compounds: Challenges and expectations

215Citations
Citations of this article
159Readers
Mendeley users who have this article in their library.

Abstract

Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imidazole) and [IndH] trans-[RuCI4(Ind)2] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms. © Schweizerische Chemische Gesellschaft.

Cite

CITATION STYLE

APA

Bratsos, I., Jedner, S., Gianferrara, T., & Alessio, E. (2007). Ruthenium anticancer compounds: Challenges and expectations. Chimia, 61(11), 692–697. https://doi.org/10.2533/chimia.2007.692

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free